Dynavax Technologies | DVAX - Cash And Equivalent

Stock Price
9.70
Daily Change
-0.36 -3.58%
Monthly
-7.40%
Yearly
-10.76%
Q3 Forecast
9.98

Dynavax Technologies reported $99.1M in Cash and Equivalent for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 918.45M
Cash and Equivalent USD 99.1M
Cost of Sales USD 14.04M
Current Assets USD 785.71M
Current Liabilities USD 118.23M
Debt USD 260.51M
EBIT USD 10.86M
EBITDA USD -21.59M
Employees 405
EPS Earnings Per Share USD 0.14
Equity Capital and Reserves USD 494.16M
Gross Profit on Sales USD 78.57M
Interest Expense on Debt USD 1.64M
Interest Income USD 7.74M
Loan Capital USD 220.75M
Market Capitalization USD 1.27B
Net Income USD 18.72M
Operating Expenses USD 81.01M
Operating Profit USD 10.86M
Ordinary Share Capital USD 117.23M
PE Price to Earnings USD 47.66
Pre-Tax Profit USD 21.22M
Sales Revenues USD 95.44M
Selling and Administration Expenses USD 41.54M
Stock USD 75.69M
Trade Creditors USD 2.7M
Trade Debtors USD 73.35M

Cash And Equivalent Change Date
AbbVie USD 5.18B 349M Mar/2025
Adma Biologics USD 90.28M 12.87M Jun/2025
Amgen USD 8.03B 782M Jun/2025
AstraZeneca USD 7.06B 1.83B Jun/2025
Biogen USD 2.76B 160.5M Jun/2025
BioMarin Pharmaceutical USD 1.21B 601.78M Jun/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Dynavax Technologies USD 99.1M 562.24M Jun/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
Glaxosmithkline GBP 3.6B 271M Jun/2025
Merck USD 8.01B 622M Jun/2025
Neurocrine Biosciences USD 264M 69.9M Jun/2025
Novartis USD 6.66B 410M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
Regeneron Pharmaceuticals USD 2B 1.09B Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024
Sarepta Therapeutics USD 510.6M 269.73M Jun/2025
TG Therapeutics USD 278.86M 146.72M Jun/2025
Vertex Pharmaceuticals USD 6.38B 1.71B Jun/2025